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OBJECTIVES: The objective of the study is comparing the cost-
effectiveness ratios, between vildagliptin 100 mg, sitagliptin
100 mg, rosiglitazone 8 mg and pioglitazone 30 mg as add-on
therapy in patients with failure to metformin. METHODS: A
meta-analysis of published rosiglitazone, pioglitazone, sitagliptin
and vildagliptin trials with failure to metformin were performed.
A decision analytic model with a decision tree with Bayesian
approach was developed. Cost-effectiveness analysis was made.
Resources utilization included emergency room patients, outpa-
tients and hospital inpatients services, drugs, etc. Data were
obtained from hospital records. The information was validated
by an expert panel. The unit costs were gotten from the Mexican
Institute of Social Security (IMSS). The perspective was from
IMSS. Analysis was conducted on a 12-month period and dis-
counting rate was not used. An incremental cost-effectiveness
ratio and incremental net beneﬁts were obtained. One-way, two-
way and probabilistic sensitivity analyses were performed and
acceptability curves were constructed. RESULTS: The lower
expected cost was with vildagliptin US$1,434, while higher
expected cost was with pioglitazone US$5033, the lowest cost
per succesfull unit was the one based on vildagliptin US$1304,
while the highest was the one based on sitagliptin US$5136.
ICER analyses show that vildagliptin was a dominant alternative
over sitagliptin, pioglitazone and rosiglitazone. The incremental
net beneﬁts were higher for vildaglitin strategy in independent
way to willingness to pay. Results were robust to sensitivity
analyses. CONCLUSION: Vildagliptin 100 mg was dominant
therapy as add on therapy in patients with failure to metformin
over sitagliptin, rosiglitazone y pioglitazone in DM 2 patients.
PDB3
COMPARING EFFICIENCY OF INSULIN GLARGINEVS. NPH
INSULIN IN PATIENTS WITHTYPE 2 DIABETES
Kodela B1, Petrovic J2,Velickovic-Radovanovic R2, Lilic R2,
Radenkovic S2, Dedovic I3
1Pharmaceutical Institution, Nis, Serbia and Montenegro, 2Clinical
Centre, Nis, Serbia and Montenegro, 3Faculty of Farmacy, Nis, Serbia
and Montenegro
OBJECTIVES: A large number of patients with type 2 diabetes
require application of insulin in the course of the disease. Because
of increasing application of basal analogues in the therapy, the
purpose of this paper is to compare the efﬁciency of application
of insulin glargine with NPH insulin. METHODS: At Endocri-
nology Clinic in Nis patients were observed who previously
received NPH insulin once a day and then switched to glargine
therapy once a day. Glycemia values were analyzed expressed in
mmol/L and HbA1C in %. Laboratory values of glycemic status
were observed before the application of glargine insulin and after
its three-month application. At the same time records were kept
concerning diabetes complications, associated diseases and oral
anti-diabetics therapy. RESULTS: In the 2003–2006 period there
was a 32% increase in the number of patients with type 2
diabetes on insulin therapy. This research included 57 patients in
total. The average fasting glycemia value in patients on NPH
insulin was 10.4 mmol/L while HbA1C level was 9.8%. After
three months of application of glargine insulin the average
fasting glycemia value was 7.9 mmol/L and HbA1C was 7.4%.
The average reduction of HbA1C in three months of application
of insulin glargine was 1.8% (p > 0.001). The most commonly
registered complications of diabetic patients were retinopathy
(58%) and neuropathy (67%). The most commonly associated
disease with diabetes was hypertension (35%). Along with
insulin therapy, the most commonly used oral diabetics are from
sulfonylurea group (46%) and biguanidines (51%). CONCLU-
SION: Based on performed researches and received results
we can conclude that the application of insulin glargine is
more efﬁcient compared to insulin NPH because it achieves
better glyco-regulation therapy slowing and delaying diabetes
complications.
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OBJECTIVES: The inhibitors of the DPP-4 has been shown to
enhance the physiological effects of incretin hormones such as
glucagone-like peptide and glucose-dependent insulinotropic
peptide thereby increasing fÑ-cells and ]-cells sensitivity
to glucose. The objective of the study is comparing the
cost-effectiveness ratios, between vildagliptin 100 mg, sitag-
liptin 100 mg, rosiglitazone 8 mg and pioglitazone 30 mg.
METHODS: A meta-analysis of published rosiglitazone, piogli-
tazone, sitagliptin and vildagliptin trials were performed the
effectiveness were obtained by means of a ﬁt put-analysis
according to the basal one of HbA1c of 9%. A decision ana-
lytic model with a decision tree with Bayesian approach was
developed. Cost-effectiveness analysis was made. Resources uti-
lization included emergency room patients, outpatients and
hospital inpatients services, drugs, etc. Data were obtained
from hospital records. The information was validated by an
expert panel. The unit costs were gotten from the Mexican
Institute of Social Security (IMSS). The perspective was from
IMSS. Analysis was conducted on a 12 month period and dis-
counting rate was not used. An incremental cost-effectiveness
ratio and incremental net beneﬁts were obtained. One-way,
two-way and probabilistic sensitivity analyses were performed
and acceptability curves were constructed. RESULTS: The
lower expected cost was with vildagliptin US$9176, while
higher expected cost was with pioglitazone US$12,002, the
lowest cost per succesfull unit was the one based on vildagliptin
US$8,342, while the highest was the one based on sitagliptin
US$16,718. Incremental cost-effectiveness ratio (ICER) analyses
show that vildagliptin was a dominant alternative over sitaglip-
tin, pioglitazone and rosiglitazone. The incremental net beneﬁts
were higher for vildaglitin strategy in independent way to will-
ingness to pay. Results were robust to sensitivity analyses.
CONCLUSION: Vildagliptin 100 mg dominant is the dominant
alternative as monotherapy over sitagliptin, rosiglitazone y
pioglitazone in type 2 diabetic patients.
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